Cinquefoil

Cinquefoil (Potentilla spp.): A Comprehensive Reference

1. Identity and Botanical Classification

Nomenclature and Taxonomy

The genus Potentilla belongs to the Rosaceae family, subfamily Rosoideae, and is commonly known as cinquefoils. Species are annual and less commonly biennial, herbaceous plants and small shrubs. The genus consists of approximately 700 species of annual, and less commonly biennial, plants and small shrubs. The genus name Potentilla originates from the Latin diminutive of potens, meaning "powerful," reflecting the medicinal properties of some species. The genus is mainly distributed in temperate, arctic, and alpine zones of the Northern Hemisphere.

The common name "cinquefoil" comes from the French word cinq, meaning five, and feuille, meaning leaf, referring to the plant's distinctively shaped leaves that typically feature five leaflets. They are known as Cinquefoils in English and Ratanjot in Hindi.

Common tormentil, P. erecta, was known as tormentilla in medieval Latin, derived from early Spanish—literally "a little torment," meaning pain that, while not debilitating, is unpleasant and persistent, such as a stomach ache, against which P. erecta was used. The name was formally established by Carl Linnaeus in his Species Plantarum (1753), where he included the genus within the family Rosaceae and designated P. reptans (creeping cinquefoil) as the type species based on specimens from European clay soils.

Principal Medicinal Species

The most studied species, both in Russia and abroad, are P. alba, P. erecta, P. recta, and P. anserina. The following are the species most commonly encountered in phytomedicine and dietary supplement contexts:

• Potentilla erecta (L.) Raeusch. — Erect cinquefoil, tormentil, bloodroot. Synonyms include Potentilla tormentilla Crantz. and Tormentilla erecta L. The rhizome is the primary medicinal part. The tormentil or erect cinquefoil is widespread throughout Europe and northern Asia, growing on wet and dry meadows, heaths, and in forests.
• Potentilla anserina L. — Silverweed. A low-growing herbaceous plant of the Rosaceae family, found in the temperate zone around the globe and most commonly on sandy or rocky clay soils in Europe, Siberia, the Far East, and Central Asia.
• Potentilla reptans L. — Creeping cinquefoil, European cinquefoil. Belongs to the least-studied plants from the Rosaceae family, Potentilla genus.
• Potentilla alba L. — White cinquefoil. The first report treating P. alba use dates from 1543 in the New Kreüterbuch by Leonhard Fuchs.

Morphological Description

Potentilla erecta is a small herbaceous plant with four yellow petals belonging to the Rosaceae family. This unusual four-petaled flower distinguishes it from most other cinquefoil species. The rhizome of the bloodroot is bulbous to cylindrical, dark brown on the outside, and quickly turns reddish on cut surfaces. When dried, the rhizome is reddish-brown, which has earned the plant the name "bloodroot."

The creeping cinquefoil (P. reptans) typically reaches a height of 10 to 30 cm and features compound leaves consisting of five to seven leaflets that are typically serrated and offer a rich green coloring. In spring and summer, it produces yellow flowers approximately 2 to 3 cm in diameter. Each bloom has five petals, consistent with the "cinque" (meaning five in French) in its name.

Pharmacopoeial Status and Common Forms

Potentilla erecta is a medicinal plant described under its traditional name Tormentil in medieval herbal books and used until today in many European countries. Monographs for Tormentillae rhizoma in the European Pharmacopoeia, as well as a monograph of the Herbal Medicinal Product Commission as a drug for traditional use, exist.

Several pharmacopoeias contain monographs on Potentilla species, including the European Pharmacopoeia 6 (2007) and the Polish Pharmacopoeia VI (2002). Tormentillae tinctura (Potentilla erecta rhizomes) is official in the European Pharmacopoeia (drug-to-extract ratio 1:5, solvent: ethanol 70% v/v, containing a minimum 1.5% m/m of tannins, expressed as pyrogallol). Tormentil rootstock has been classified by the HMPC as a traditional herbal medicinal product (Article 16a of Directive 2001/83/EC).

Potentilla is available in commercial forms for oral intake, as well as in crude and powder forms. Forms found in trade include dried rhizome, powdered rhizome, hydroethanolic tinctures, dry extracts in capsules or tablets, and herbal teas. Several Potentilla species — including P. erecta (rhizomes), P. anserina (aerial parts or whole plant), P. aurea (aerial part), and P. reptans (aerial part) — are also used to prepare homeopathic medications according to the homeopathic pharmacopoeias (HPUS, HAB).

2. Traditional and Historical Use

Ancient and Classical Period

The genus Potentilla is mainly distributed in temperate, arctic, and alpine zones of the Northern Hemisphere and has been known since ancient times for its curative properties. Use of cinquefoil was noted as early as Roman times; Pliny the Elder (23–79 CE) described pentaphyllon—identified as Potentilla reptans—in his Natural History for its astringent and healing qualities derived from its five-petaled flowers and leaflets.

Medieval European Use

The first report treating P. alba use dates from 1543 in the New Kreüterbuch by Leonhard Fuchs. One of the species described was white cinquefoil ("Groß Weiss Fünffingerkraut"), of which the underground parts were used externally to treat inflammation of the mouth and throat and toothache. Internal use described for the underground parts included the treatment of dysentery, ulcers, and jaundice. Aerial part application included the treatment of fever, jaundice, fistula, and as an astringent.

Silverweed (P. anserina) has long been a medicinal plant, as noted in the herbals of both Gerard and Culpepper. Since ancient times, the European cinquefoil (Potentilla reptans) has been traditionally used in herbal medicine for treatment of toothache, ulcers, and inflammation of the throat, as well as certain forms of cancer, infections due to bacteria, fungi and viruses, diarrhea, diabetes mellitus, and other ailments.

Traditional Chinese and Tibetan Medicine

Potentilla anserina, belonging to the Rosaceae family, is a medicinal herb with a long history of use in Tibetan medicine in China. Its swollen tuberous root is a medicinal food known as "jue ma" in Chinese. Remedies containing P. anserina total herb are widely used in various folk and medical systems, particularly in traditional Tibetan medicine and folk medicine. In Tibetan medicine, P. anserina herb is used for infectious diarrhea with fever, while its roots and rhizomes are applied as an antiseptic remedy.

Ancient Chinese medical works, in particular the Compendium of Chinese Materia Medica and Mingyi Bielu, mentioned cinquefoil species as valuable phytomedicines against diarrhea, ulcers, fever, jaundice, oral inflammations, topical infections, and thyroid gland disorders.

Traditional Preparations and Uses

Extracts of the aerial and/or underground parts have been applied in traditional medicine for the treatment of inflammations, wounds, certain forms of cancer, infections due to bacteria, fungi and viruses, diarrhea, diabetes mellitus, and other ailments.

The rhizome of P. erecta has traditionally been used as an antidiarrheal, hemostatic, and antihemorrhoidal remedy. Remedies were made from the flowers, leaves, roots, and whole plants, depending on the condition. Ancient remedies came in decoctions, elixirs, teas, tinctures, tonics, powders, and poultices, frequently mixed with other herbs, alcohol, honey, or beeswax.

P. anserina is commonly used in the treatment of diarrhea, coughs, malnutrition, and various types of hemorrhagic disorders. The whole plant is antispasmodic, mildly astringent, diuretic, haemostatic, odontalgic, and tonic. A strong infusion is used to check the bleeding of piles and to treat diarrhea; it is also used as a gargle for sore throats. Externally, it is used as a powder to treat ulcers and hemorrhoids, while the whole bruised plant, placed over a painful area, acts as a local analgesic.

The therapeutic indications of the herbal parts of Potentilla anserina and the rhizomes of Potentilla erecta include, according to the German Commission E, simple forms of dysmenorrhea, the supporting therapy of simple forms of unspecific, acute diarrhea, and also simple forms of mucosal inflammations of throat and mouth.

3. Phytochemistry: Key Constituents and Active Compounds

Tannins and Ellagitannins

P. erecta contains up to 20% tannins and 5% ellagitannins, mainly agrimoniin. Tannins are grouped into hydrolyzable tannins, consisting of gallic acid and/or ellagic acid and sugar moieties, and condensed tannins or proanthocyanidins, composed of flavanols, especially catechin, forming oligo- to polymeric molecules.

The main components of tormentil rhizomes are procyanidin B3 (mean ~3.6%), procyanidin C2 (mean ~2.8%), agrimoniin (mean ~2.5%), 3-O-galloylquinic acid (mean ~1.7%), catechin (mean ~1.6%), other flavan-3-ol oligomers (mean ~0.5–1.1%), and laevigatins (mean ~0.2–0.6%). Free ellagic acid and glycosides of ellagic and methylellagic acids are secondary components. Underground parts of tormentil are a source of oligomeric proanthocyanidins and ellagitannins, but in smaller quantity of gallotannins.

The rhizome of P. erecta contains a high amount of hydrolyzable tannins, the dominating of which is agrimoniin, a dimeric ellagitannin with a molecular weight of 1862 Da. Ellagitannins identified in commercial samples include pedunculagin (1%), agrimoniin (3.5%), laevigatin B, and laevigatin F.

Potentilla anserina contains tannins (5 to 10%), chiefly ellagitannins, as well as flavonoids including quercitrin, and hydroxycoumarins such as umbelliferone and scopoletin. The major components of interest in Potentilla species are tannins of the ellagic-acid type, with monomeric and dimeric ellagitannins. The herb also contains antioxidant flavonoids (quercetin and myricetin glycosides) and proanthocyanidins. Another group of components of silverweed being investigated is the long- and medium-chain polyprenols, which accumulate in the leaves of P. anserina at a concentration of up to 0.3% fresh weight.

Flavonoids and Phenolic Acids

According to previous studies, the main components of P. anserina are flavonoids, triterpenes, and phenolic acids. Various constituents such as sterols, caffeic acid, gallic acid, ellagic acid, quercetin, and kaempferol have been characterized across Potentilla species.

Different groups of compounds such as chlorogenic acid, kaempferol 3-O-rutinoside, acacetin 7-O-rutinoside, and genistein were reported for the first time in P. anserina. A recent review identified over 200 compounds from Potentilla species, many of them from P. anserina.

Antioxidant Profile

Tannins, especially ellagitannins with agrimoniin, as well as total polyphenols, have the greatest influence on antioxidant activity in the ABTS test. Bos et al. (1996) investigated tormentil and found that the dimers and trimers inhibited lipid peroxidation, and pentamers and hexamers inhibited the enzyme elastase.

4. Mechanisms of Action

Astringency and Gastrointestinal Effects

Potentilla contains chemicals called tannins that might help reduce skin inflammation and have a drying (astringent) effect on the tissues. Tannins also have a drying effect. This effect might help control diarrhea and stop bleeding. The high tannin content creates protein-precipitating effects at mucosal surfaces, which underlies both the antidiarrheal and astringent activities observed across the genus.

Anti-Inflammatory Activity via COX-2 Inhibition

Potentilla species that have been investigated display pharmacological activity mainly due to the presence of polyphenols. It was shown that polyphenol-rich extract from the rhizome of Potentilla erecta (tormentil extract) affects the metabolism of arachidonic acid and exerts both anti-inflammatory and anti-oxidant activities.

P. erecta fractions were analyzed in HaCaT keratinocytes for the expression of cyclooxygenase-2 (COX-2) induced by ultraviolet-B (UVB) irradiation. As COX-2 catalyzes the metabolism of arachidonic acid to prostanoids such as PGE2, PGE2 concentration in cell culture supernatants was measured. P. erecta inhibited UVB-induced COX-2 expression in HaCaT cells and dose-dependently reduced PGE2.

Agrimoniin and Histamine Inhibition

Agrimoniin is a hydrolyzable tannin that is a potent radical scavenger. Agrimoniin was shown to be a very good inhibitor of oxidative stress-induced histamine release from rat peritoneal mast cells. It was approximately 20 times more effective than EGCG, the main tannin of green tea, and comparable to the best anti-allergic drug Azelastine. Agrimoniin (or an agrimoniin-rich acetonic fraction) also has outstanding capacities as an antioxidant, astringent, and elastase inhibitor.

Uterine Tonic Effects

The gynecological indication for silverweed (Potentilla anserina) is based on pharmacological studies showing that the herb increases the tonus of the isolated uterus in various animal species. On isolated rat uterus, a paralyzing effect was also proven, which is due to the presence of ammonium salts. The empirical evidence of a spasmolytic effect in dysmenorrhea could not be definitively proven.

Antimicrobial Activity

Bioactive compounds present in Potentilla species possess antimicrobial, antidiarrheal, and antitumor properties. Most species of the genus Potentilla contain hydrolysable tannins, proanthocyanidins, flavonoids, and triterpenes as bioactive substances, which together contribute to broad-spectrum antimicrobial activity demonstrated in multiple in vitro investigations.

Wound Healing

Methanolic extract of P. erecta (MEPE) significantly increased wound contraction rate compared to the diabetic control group on days 3 and 7. MEPE-treated rats showed a statistical increase in the levels of nitric oxide (NOx), glutathione (GSH), and collagen, and a statistical decrease in the levels of thiobarbituric-acid reactive substances (TBARs). This suggests roles for both antioxidant protection and collagen synthesis promotion in wound healing.

5. Scientific Evidence by Area of Use

5.1 Diarrhea (Rotavirus-Induced, Pediatric)

Evidence strength: Moderate (one small RCT)

A randomized, double-blind, controlled trial published in the Pediatric Infectious Disease Journal (2003) showed that controlled doses of tormentil root extract (Potentilla tormentilla) shorten the duration of rotavirus diarrhea in children. The treatment, long used in European folk medicine to manage diarrhea, also reduces the amount of fluid loss associated with the condition.

The randomized, double-blinded, placebo-controlled trial was conducted at Children's Hospital for Infectious Diseases #3, St. Petersburg, Russia, in 40 children ranging in age from 3 months to 7 years with rotavirus diarrhea. Twenty children received tormentil root extract; 20 patients were given a placebo of Indian tea made to look and taste like tormentil. All patients received three drops of tormentil root extract or placebo per year of life, three times daily until discontinuation of diarrhea, or a maximum of five days.

The duration of diarrhea in the tormentil root extract treatment group was 3 days, compared with 5 days in the control group (P < 0.0001). In the treatment group, 8 of 20 (40%) children were diarrhea-free 48 hours after admission to the hospital, compared with 1 of 20 (5%) in the control group (P < 0.0001). Subjects in the treatment group received smaller volumes of parenteral fluids than those in the control group. The administration of tormentil root extract in controlled doses shortened the duration of rotavirus diarrhea and decreased the requirement for rehydration solutions.

This is a significant positive result, but the study enrolled only 40 participants and has not been replicated in larger trials. The evidence for this specific indication is promising but limited by the small sample size and single study.

5.2 Inflammatory Bowel Disease (Ulcerative Colitis)

Evidence strength: Preliminary (one open-label dose-escalation study)

Tormentil extracts (TE) have antioxidative properties and are used as a complementary therapy for chronic inflammatory bowel disease. In individual patients with ulcerative colitis (UC), positive effects have been observed. The study goal was to assess the safety, pharmacology, and clinical effects of different doses of TE in patients with active UC.

Sixteen patients with active UC (clinical activity index [CAI] ≥5) received TE in escalating doses of 1200, 1800, 2400, and 3000 mg/day for 3 weeks each. Each treatment phase was followed by a 4-week washout phase. During therapy, the CAI decreased in all patients, whereas it increased during the washout phase. TE appeared safe up to 3000 mg/d, and neither undegraded nor metabolized tannins could be detected by liquid-mass spectrometry (LC-MS) in patient sera, suggesting that tannin levels are not systemically absorbed.

It is worth noting that up to 2009 only two clinical studies on P. erecta rhizome extracts had been published: the study by Huber et al. (2007) on the efficacy in active ulcerative colitis, and the study by Subbotina et al. (2003) on the efficacy in rotavirus-induced diarrhea in children. The open-label, uncontrolled design of the UC study means results must be interpreted cautiously; no placebo-controlled trial has subsequently confirmed these findings.

5.3 Anti-Inflammatory and Dermatological Effects

Evidence strength: In vitro only (cell-based models)

Researchers tested the anti-inflammatory effect of four P. erecta fractions with increasing amounts of agrimoniin in HaCaT keratinocytes. The expression of COX-2 induced by ultraviolet-B (UVB) irradiation was analyzed. P. erecta inhibited UVB-induced COX-2 expression in HaCaT cells and dose-dependently reduced PGE2. No published controlled human trials on topical cinquefoil preparations for inflammatory skin conditions have been identified.

5.4 Wound Healing

Evidence strength: Preclinical animal models only

As stated in many ethnobotany studies, the Potentilla genus is traditionally used in the treatment of wound healing. In one study, researchers investigated the effects of methanolic extract of P. erecta (MEPE) on diabetic wounds. The experiments involved 36 Wistar rats divided into three groups: non-diabetic control, diabetic control, and P. erecta-treated. Diabetes was induced by streptozotocin. Full-thickness excisional skin wounds were opened in rats, and the wounds were treated with P. erecta root extract in the MEPE groups. Significant improvements in wound contraction and biochemical markers of healing were observed. Human clinical evidence for wound healing applications does not yet exist.

5.5 Anticancer Properties

Evidence strength: In vitro and preclinical only

The aim of one study was to investigate potential antitumor activity of aqueous extracts (rhizome and aerial parts) of P. reptans on the 4T1 mouse breast cancer cell line. Aqueous extracts of rhizome and aerial parts were tested for cytotoxicity by the MTT colorimetric assay in a concentration range of 100–800 µg/mL. Aqueous extracts showed concentration-dependent cytotoxic effect, though P. reptans demonstrated weak cytotoxic activity on this cell line. The results represent the first report on cytotoxicity for this plant, and further research on human cell lines is indicated.

P. reptans exhibited also high antiproliferative activity against MCF-7 cells. The results suggest that Potentilla species could be potential candidates for developing new phyto-pharmaceuticals and functional ingredients. All anticancer evidence is preclinical; no human clinical trials have been conducted.

5.6 Antidiabetic Activity

Evidence strength: In vitro and animal studies only

Some Potentilla species have been used for their antidiabetic effects in folk medicines. Pharmacological properties can be explained by the presence of a variety of phytochemicals derived from different parts of the plant. Extracts from the aerial and/or underground parts have been applied in traditional medicine and exhibit antioxidant, hypoglycemic, anti-inflammatory, antitumor, and anti-ulcerogenic properties. No controlled human clinical trials specifically evaluating cinquefoil for glycemic management have been published to date.

5.7 Antithrombotic Potential

Evidence strength: Preclinical animal models only

Polyphenol-rich extract from the rhizome of Potentilla erecta (tormentil extract) affects the metabolism of arachidonic acid and exerts both anti-inflammatory and anti-oxidant activities, suggesting a possible effect on thrombosis. This remains at the preclinical stage; no human studies have been conducted.

5.8 Gynecological Uses (Dysmenorrhea)

Evidence strength: Pharmacological (animal) studies; Commission E–endorsed traditional use

The gynecological indication for P. anserina is based on pharmacological studies showing that the herb increases the tonus of the isolated uterus in various animal species. The German Commission E Monographs approve Potentilla anserina (silverweed) for diarrhea, inflammation of the mouth and pharynx, and premenstrual syndrome. No robust controlled human trials specifically confirming efficacy in dysmenorrhea are available.

5.9 Oral Mucosal Inflammation

Evidence strength: Traditional use supported by pharmacological rationale; limited clinical data

ESCOP indicates tormentil rhizome internally for non-specific, acute diarrheal diseases and supportively for acute and chronic intestinal inflammation; externally for slight irritations of the mucosa of the mouth and throat; these indications are based on human experience and long-standing use. The astringent activity of tannins provides a plausible pharmacological rationale, but dedicated clinical trials are lacking.

6. Body Systems and Health Areas Associated with Cinquefoil

• Gastrointestinal system: In vitro and in vivo pharmacological studies have reviewed antidiarrhoic and anti-ulcerogenic activities of Potentilla species.
• Immune and inflammatory system: Anti-inflammatory activity via COX-2 inhibition and PGE2 reduction demonstrated in cell models.
• Skin and wound healing: The Potentilla genus is traditionally used in the treatment of wound healing.
• Gynecological/reproductive system: Traditional and pharmacological basis for dysmenorrhea and PMS applications in P. anserina.
• Oral mucosa: Astringent application for mouth and throat inflammation, supported by long-standing use.
• Cardiovascular system: Research areas include antioxidant and hepatoprotective effects, as well as therapeutic effects of P. anserina extract on cardiovascular diseases.
• Antimicrobial defense: P. anserina exhibits excellent pharmacological activities such as anti-inflammatory, antibacterial, and immunomodulatory properties.

7. Dosage Forms and Reported Dosages

Oral Preparations

• Herbal tea (P. anserina): To prepare a tea, boiling water is poured over 2 g of finely cut drug and strained after 10 minutes (1 teaspoon corresponds to approximately 0.7 g of drug). The daily dosage is 4 to 6 g of drug; as tea: 1 cup freshly prepared, several times a day between meals.
• Tormentil extract (ulcerative colitis study, adults): Sixteen patients with active UC received TE in escalating doses of 1200, 1800, 2400, and 3000 mg/day for 3 weeks each.
• Tormentil root extract (pediatric rotavirus diarrhea): Patients received three drops of tormentil root extract or placebo per year of life, three times daily, until discontinuation of diarrhea or a maximum of five days.
• Tormentillae tinctura (European Pharmacopoeia): Defined with a drug-to-extract ratio of 1:5, solvent ethanol 70% (v/v), containing a minimum of 1.5% (m/m) of tannins expressed as pyrogallol.

Tannin Content Reference Values

Commercial tormentil plant material is characterized by a high content of tannins and related polyphenols, at levels above 20% in rhizomes and above 2% in tinctures. The main components of tormentil tinctures were oligomeric tannins with an average content of 5.26 mg/g, procyanidin C2 (3.36 mg/g), and agrimoniin (2.05 mg/g).

8. Safety Considerations and Interactions

General Tolerability

Potentilla extracts are presumed to be safe, and no toxic effects have been reported when applied to humans. Shushunov et al. (2009) worked on P. erecta and concluded that no toxicity was displayed by the given rhizome extracts even at elevated concentrations. Mincheva et al. (2018) highlighted the antimicrobial potential of P. reptans and further confirmed the non-toxic nature of the plant extracts.

Potentilla seems safe for most people but can cause stomach irritation.

Systemic Absorption of Tannins

During tormentil therapy (doses up to 3000 mg/day), neither undegraded nor metabolized tannins could be detected by liquid-mass spectrometry (LC-MS) in patient sera. This finding suggests that the tannins in tormentil extracts do not accumulate systemically at detectable levels under tested oral dosing conditions.

Drug Interactions

According to EMA/ESCOP monograph data, oral administration of Potentilla rhizome preparations may delay the absorption of other orally administered medications. This is consistent with the general pharmacological behavior of high-tannin preparations, which can bind proteins and alkaloids in the gastrointestinal tract, potentially reducing the bioavailability of concurrently administered drugs. Based on this, cinquefoil preparations should be administered separately in time from other oral medications.

The use of tormentil in inflammatory bowel disease and in irritable bowel syndrome where diarrhea is the predominant symptom has been linked to the antioxidant activity of polyphenols. Patients taking anticoagulants, anti-inflammatory drugs, or medications with narrow therapeutic windows and oral bioavailability concerns should be aware of the potential for tannin-mediated absorption interference.

Pregnancy and Lactation

There is not enough known about the use of potentilla during pregnancy and breast-feeding to assess safety. In the context of P. anserina (silverweed), the uterotonic pharmacological activity documented in animal studies warrants particular caution.

Gaps in Safety Evidence

Plants of the genus Potentilla have been studied fragmentarily; among the representatives of the genus, most species are unstudied. As with much herbal medicine, what is lacking so far is clinical evidence. Long-term safety data, systematic evaluations in specific patient populations, and interaction studies with commonly used pharmaceuticals remain largely unavailable for most cinquefoil species beyond P. erecta.

9. Evidence Appraisal Summary

Up to 2009, only two clinical studies on P. erecta rhizome extracts had been published: the study by Huber et al. (2007) on the efficacy in active ulcerative colitis, and the study by Subbotina et al. (2003) on the efficacy in rotavirus-induced diarrhea in children. At that time, several in vitro and in vivo studies had been performed confirming the traditional use of various Potentilla species. The overall clinical evidence base remains modest. The most robustly verified applications are the traditional uses recognized by the German Commission E and ESCOP — namely, diarrhea, mild oral mucosal inflammation, and (for silverweed) dysmenorrhea — supported by plausible pharmacological mechanisms. Future efforts should concentrate more on in vitro and in vivo studies and on clinical trials to confirm traditional wisdom in the light of rational phytotherapy.

References

• Hoffmann J et al. Anti-Inflammatory Effects of Agrimoniin-Enriched Fractions of Potentilla erecta. Molecules. 2016;21(6):792. PMC6273098.
• Huber R et al. Tormentil for active ulcerative colitis: an open-label, dose-escalating study. J Clin Gastroenterol. 2007;41(9):834–838. PubMed PMID: 17881930.
• Subbotina MD et al. Effect of oral administration of tormentil root extract (Potentilla tormentilla) on rotavirus diarrhea in children: a randomized, double blind, controlled trial. Pediatr Infect Dis J. 2003;22(8):706–711. PubMed PMID: 12913771.
• Tomczyk M, Latté KP. Potentilla — A review of its phytochemical and pharmacological profile. J Ethnopharmacol. 2009;122(2):184–204. ScienceDirect.
• Holistic overview of different species of Potentilla: pharmaceutical significance. South African Journal of Botany. 2021. ScienceDirect.
• Potentilla — an overview. ScienceDirect Topics.
• Kaltalioglu K et al. Phenolic, Antioxidant, Antimicrobial, and In-vivo Wound Healing Properties of Potentilla erecta L. Root Extract in Diabetic Rats. Iran J Pharm Res. 2020. PMC8019876.
• Cytotoxic and Enzyme Inhibitory Potential of Two Potentilla species and Their Chemical Composition. PMC5441381.
• Cytotoxic effect of Potentilla reptans L. rhizome and aerial part extracts. PubMed PMID: 24147362.
• Phytochemical Profiling of Extracts from Rare Potentilla Species and Evaluation of Their Anticancer Potential. PMC10002591.
• Anticancer potential of acetone extracts from selected Potentilla species against human colorectal cancer cells. PMC9556846.
• Phytochemical composition of Potentilla anserina L. analyzed by GC-MS and LC-MS metabolomics. PMC3651535.
• Phenolic Profile of Potentilla anserina L. Herb of Siberian Origin. PMC6272682.
• Systematic review on botany, ethnopharmacology, phytochemistry and pharmacology of Potentilla anserina L. ScienceDirect. 2024.
• Antithrombotic Potential of Tormentil Extract in Animal Models. Frontiers in Pharmacology. 2017.
• Fecka I. Quantification of tannins and related polyphenols in commercial products of tormentil (Potentilla tormentilla). Phytochem Anal. 2015.
• Phytochemical profiles, antioxidant and antimicrobial activities of three Potentilla species. PMC3840622.
• Latté KP. Potentilla erecta, tormentil. ResearchGate/Z Phytotherapie review.
• Tormentil — medicinal use: indications, dosage, side effects, interactions. Arzneipflanzenlexikon (German Medicinal Plants Encyclopedia).
• New Perspectives for the Use of Potentilla alba Rhizomes. Thieme/Z Phytother. 2021.
• Sergalieva et al. Pharmacotherapeutic potential of plants of the genus Potentilla. Problems of Biological Medical and Pharmaceutical Chemistry.
• Potentilla Extract Reduces Rotavirus Diarrhea Duration in Children. Medscape Medical News, 2003.
• Potentilla. Wikipedia (taxonomy and etymology sections).
• Potentilla. Grokipedia (historical and taxonomical information).
• Plants for a Future: Potentilla anserina Silverweed.